Optimization of potassium management in patients with chronic kidney disease and type 2 diabetes on finerenone
暂无分享,去创建一个
J. Górriz | M. Soler | A. Ortíz | J. Mediavilla | R. Alcázar Arroyo | B. Fernandez-Fernandez | A. Michán-Doña | Pedro Pablo Casado Escribano | F. Martínez Debén
[1] F. An,et al. Finerenone attenuates myocardial apoptosis, metabolic disturbance and myocardial fibrosis in type 2 diabetes mellitus , 2023, Diabetology & Metabolic Syndrome.
[2] Lin Che,et al. Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus , 2023, Frontiers in Endocrinology.
[3] M. Sánchez-Niño,et al. Sodium zirconium cyclosilicate and metabolic acidosis: Potential mechanisms and clinical consequences. , 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[4] J. Górriz,et al. Cardiorenal benefits of finerenone: protecting kidney and heart , 2023, Annals of medicine.
[5] M. Soler,et al. Tirzepatide and prevention of chronic kidney disease , 2022, Clinical kidney journal.
[6] W. Cushman,et al. Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events. , 2022, The New England journal of medicine.
[7] Eric L. Johnson,et al. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2023. , 2022, Diabetes care.
[8] J. Cleland,et al. Renin-Angiotensin System Inhibition in Advanced Chronic Kidney Disease. , 2022, The New England journal of medicine.
[9] K. Tamura,et al. Cardiovascular and kidney outcomes of combination therapy with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in patients with type 2 diabetes and chronic kidney disease: a systematic review and network meta-analysis. , 2022, Diabetes research and clinical practice.
[10] G. Filippatos,et al. A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease , 2022, Clinical kidney journal.
[11] E. Rebelos,et al. Complementary actions of finerenone and SGLT2‐i on renal outcomes?: An urgent need for more information , 2022, Nephrology.
[12] M. Landray,et al. Empagliflozin in Patients with Chronic Kidney Disease , 2022, The New England journal of medicine.
[13] Connie M. Rhee,et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) , 2022, Diabetes care.
[14] Connie M. Rhee,et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). , 2022, Kidney international.
[15] Yijie Jia,et al. Network meta-analysis of mineralocorticoid receptor antagonists for diabetic kidney disease , 2022, Frontiers in Pharmacology.
[16] C. Kovesdy,et al. Potassium management with finerenone: Practical aspects , 2022, Endocrinology, diabetes & metabolism.
[17] M. Rizzo,et al. Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective , 2022, Expert opinion on drug safety.
[18] A. Ortiz,et al. Finerenona: completando el abordaje del paciente con enfermedad renal y diabetes , 2022, Nefrología.
[19] V. Montori,et al. In type 2 diabetes, SGLT2 inhibitors reduced risk for serious hyperkalemia without increasing hypokalemia , 2022, Annals of Internal Medicine.
[20] N. Tangri,et al. Balancing Hyperkalemia Risks with Clinical Benefits of Renin-Angiotensin-Aldosterone Inhibitors/Mineralocorticoid Receptor Antagonists Blockade: It’s Apples and Oranges , 2022, Kidney360.
[21] A. Singh,et al. Renin-angiotensin system blockers-SGLT2 inhibitors-mineralocorticoid receptor antagonists in diabetic kidney disease: A tale of the past two decades! , 2022, World journal of diabetes.
[22] P. de Pablos-Velasco,et al. Information and consensus document for the detection and management of chronic kidney disease. , 2022, Nefrologia.
[23] K. Campbell,et al. Role of Finerenone in the Treatment of Diabetic Kidney Disease: Patient Selection and Clinical Perspectives , 2022, Therapeutics and clinical risk management.
[24] J. McGill,et al. Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE) , 2022, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[25] E. Lerma,et al. Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes , 2022, Expert review of clinical pharmacology.
[26] G. Bakris,et al. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease , 2022, Postgraduate medicine.
[27] É. B. Rangel,et al. Hyperkalemia in Diabetes Mellitus Setting , 2022, Diseases.
[28] Deepak L. Bhatt,et al. Generalizability of FIGARO‐DKD and FIDELIO‐DKD Trial Criteria to the US Population Eligible for Finerenone , 2022, Journal of the American Heart Association.
[29] Murray Epstein. A Podcast Discussing Aldosterone and Mineralocorticoid Receptor Antagonists in 2021: A Paradigm Shift , 2022, Diabetes Therapy.
[30] M. Jardine,et al. SGLT2 inhibitors and finerenone: one or the other or both? , 2022, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[31] R. Raj. Finerenone: a new mineralocorticoid receptor antagonist to beat chronic kidney disease , 2022, Current opinion in nephrology and hypertension.
[32] Qiyan Zheng,et al. Efficacy and Safety of Finerenone in Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials , 2022, Frontiers in Pharmacology.
[33] K. Kalantar-Zadeh,et al. Taking the Kale out of Hyperkalemia: Plant Foods and Serum Potassium in Patients with Kidney Disease. , 2022, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.
[34] E. Huang,et al. 11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes-2022. , 2021, Diabetes care.
[35] S. Bell,et al. The ERA Registry Annual Report 2019: summary and age comparisons , 2021, Clinical kidney journal.
[36] T. Eissing,et al. Finerenone Dose–Exposure–Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria , 2021, Clinical Pharmacokinetics.
[37] H. Ghanim,et al. Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials , 2021, Diabetes, obesity & metabolism.
[38] W. Tu,et al. Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease. , 2021, The New England journal of medicine.
[39] G. Filippatos,et al. Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial , 2021, Journal of the American Society of Nephrology : JASN.
[40] Y. Takashi,et al. Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease , 2021, Frontiers in Pharmacology.
[41] J. Sim,et al. Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI/ARBs in patients with diabetic kidney disease , 2021, Pharmacotherapy.
[42] G. Filippatos,et al. Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy , 2021, Kidney international reports.
[43] A. Ortíz. RICORS2040: the need for collaborative research in chronic kidney disease , 2021, Clinical kidney journal.
[44] G. Filippatos,et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. , 2021, The New England journal of medicine.
[45] M. Sood,et al. Hyperkalemia with RAAS Inhibition: Mechanism, Clinical Significance, and Management. , 2021, Pharmacological research.
[46] C. Cannon,et al. Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. , 2021, European heart journal.
[47] L. Del Vecchio,et al. Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies , 2021, Drugs.
[48] M. Pavkovic,et al. Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage , 2021, American Journal of Nephrology.
[49] M. Epstein. Aldosterone and Mineralocorticoid Receptor Signaling as Determinants of Cardiovascular and Renal Injury: From Hans Selye to the Present , 2021, American Journal of Nephrology.
[50] E. Núñez,et al. Long-term mortality and trajectory of potassium measurements following an episode of acute severe hyperkalaemia , 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[51] G. Filippatos,et al. Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone , 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[52] J. Carrero,et al. Clinical Management of Hyperkalemia. , 2020, Mayo Clinic proceedings.
[53] G. Bakris,et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine , 2020, European heart journal.
[54] K. Khunti,et al. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. , 2020, Kidney international.
[55] C. Richard,et al. Handouts for Low-Potassium Diets Disproportionately Restrict Fruits and Vegetables. , 2020, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.
[56] A. Segura-Fragoso,et al. Prevalence of chronic kidney disease and associated factors in the Spanish population attended in primary care: Results of the IBERICAN study. , 2020, Medicina clinica.
[57] G. Nijpels,et al. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. , 2020, The lancet. Diabetes & endocrinology.
[58] S. Grandy,et al. Associations between serum potassium and adverse clinical outcomes: A systematic literature review , 2020, International journal of clinical practice.
[59] M. Bailey,et al. Hyperkalemia: pathophysiology, risk factors and consequences , 2019, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[60] C. Kovesdy,et al. Constipation in CKD , 2019, Kidney international reports.
[61] B. Williams,et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial , 2019, The Lancet.
[62] J. Carrero,et al. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. , 2019, Kidney international.
[63] L. Lund,et al. Recurrent hyperkalaemia management and use of renin–angiotensin–aldosterone system inhibitors: a European multi-national targeted chart review , 2019, Clinical kidney journal.
[64] B. Zinman,et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.
[65] A. Ortiz,et al. Clarifying the concept of chronic kidney disease for non-nephrologists , 2019, Clinical kidney journal.
[66] Austin Carter,et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories , 2018, The Lancet.
[67] G. Nijpels,et al. Characteristics of high‐ and low‐risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes , 2018, Diabetic medicine : a journal of the British Diabetic Association.
[68] J. Carrero,et al. Mediterranean diet as the diet of choice for patients with chronic kidney disease , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[69] A. Santoro,et al. [Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)]. , 2018, Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia.
[70] Zhuo Zhao,et al. The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure , 2018, Medicine.
[71] R. Klopfleisch,et al. Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone’s Antifibrotic Activity , 2018, Hypertension.
[72] K. Tuttle,et al. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. , 2017, Clinical journal of the American Society of Nephrology : CJASN.
[73] Xifeng Wu,et al. Diabetes with early kidney involvement may shorten life expectancy by 16 years. , 2017, Kidney international.
[74] D. Jayne,et al. SUMMARY OF PRODUCT CHARACTERISTICS , 2014 .
[75] H. Mischak,et al. Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial , 2016, BMJ Open.
[76] P. Sarafidis,et al. Prevalence of Hyperkalemia in Diabetic and Non-Diabetic Patients with Chronic Kidney Disease: A Nested Case-Control Study , 2015, American Journal of Nephrology.
[77] N. Oestreicher,et al. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. , 2015, The American journal of managed care.
[78] L. Ruilope,et al. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. , 2015, JAMA.
[79] M. Lombès,et al. Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1* , 2015, The Journal of Biological Chemistry.
[80] B. Silke,et al. Serum potassium levels as an outcome determinant in acute medical admissions. , 2015, Clinical medicine.
[81] C. Kovesdy. Management of hyperkalaemia in chronic kidney disease , 2014, Nature Reviews Nephrology.
[82] P. Ponikowski,et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial , 2013, European heart journal.
[83] M. Kemper,et al. Pathogenesis, diagnosis and management of hyperkalemia , 2010, Pediatric Nephrology.
[84] Alexander Hillisch,et al. A New Mode of Mineralocorticoid Receptor Antagonism by a Potent and Selective Nonsteroidal Molecule* , 2010, The Journal of Biological Chemistry.
[85] E. Lewis,et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.
[86] B. Brenner,et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.
[87] R. Bain,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.
[88] OUP accepted manuscript , 2021, European Heart Journal.
[89] OUP accepted manuscript , 2021, Nephrology Dialysis Transplantation.
[90] Á. D. de Francisco,et al. Epidemiology of hyperkalemia in chronic kidney disease. , 2019, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.
[91] G. Filippatos,et al. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside. , 2017, Handbook of experimental pharmacology.
[92] B. Brenner,et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy , 2002 .
[93] A Fournier,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1994, The New England journal of medicine.
[94] J. Uribarri,et al. Hyperkalemia in diabetes mellitus. , 1990, The Journal of diabetic complications.